Home / Peptides / Bremelanotide

Bremelanotide (PT-141) Dosage Chart and Schedule

FDA-approved

Melanocortin agonist (Vyleesi) approved for low sexual desire in premenopausal women. 1.75 mg as needed.

Also called: PT-141, Vyleesi

Regulatory status (US)

FDA-approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not the same drug as melanotan II.

What it is

A melanocortin receptor agonist, a cyclic peptide related to alpha-MSH.

Label dose (Vyleesi)

DoseWhenLimits
1.75 mg under the skin (autoinjector)At least 45 minutes before sexual activityNo more than 1 dose in 24 hours; more than 8 doses a month is not recommended

From the Vyleesi prescribing information. Stop after 8 weeks if there is no improvement.

Bremelanotide reconstitution calculator

Enter your vial and your prescribed dose to see the units on a U-100 syringe.

–
Concentration–
Per 1 unit (0.01 mL)–
Volume per dose–
Doses per vial–

What human studies show

Safety

Questions

Is Bremelanotide FDA-approved?
FDA-approved in June 2019 as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Not the same drug as melanotan II.
What dose of Bremelanotide has been studied?
1.75 mg under the skin (autoinjector): At least 45 minutes before sexual activity: No more than 1 dose in 24 hours; more than 8 doses a month is not recommended. From the Vyleesi prescribing information. Stop after 8 weeks if there is no improvement.
How many units is my Bremelanotide dose?
Divide the mg in the vial by the mL of bacteriostatic water to get mg/mL, divide your dose in mg by that, and multiply by 100 for units on a U-100 syringe. The calculator on this page does it and draws the syringe.

Related

Tirzepatide

Weekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.

Semaglutide

Weekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).

Orforglipron (Foundayo)

Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.

Tesamorelin

GHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.

Sources

  1. Vyleesi (bremelanotide) prescribing information (Drugs.com label mirror)
  2. FDA 510(k) K212499: BD insulin syringes for U-100 insulin

Last checked 2026-11-16. How we pick and check sources: methodology.